Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Among diffuse large B cell lymphoma (DLBCL) patients, determining the appropriate dose and chemotherapy schedule to balance toxicity and efficacy is harder in elderly than in younger patients. Moreover, there are no currently available clinical factors that consistently identify patients who are unfit to receive chemotherapy. Therefore, the clinical characteristics and outcomes of elderly patients with DLBCL and the causes of treatment-related death were investigated in this study. Methods: The clinical characteristics and outcomes of 44 elderly (≥ 70 years of age) patients diagnosed with DLBCL between January 2005 and June 2013 were evaluated. Variable clinical data along with the response rate, overall survival (OS), and causes of treatment-related death or treatment interruption were investigated. Results: The median OS was 18.6 months, and 19 patients completed curative treatment. The mean average relative dose intensity of adriamycin in patients who completed chemotherapy was 0.617, and of these patients, 16 achieved complete remission. Chemotherapy incompletion, infectious complications, extranodal involvement, high lactate dehydrogenase, poor performance status, and low albumin level at diagnosis were related to a shorter OS. However, multivariate analysis revealed that only infections and chemotherapy incompletion were significantly related to poor prognosis. The most common cause of treatment-related death was infection, and patients who had experienced infectious complications tended to have lower albumin levels than those of patients without such complications. Conclusions: In the treatment of elderly lymphoma patients, the dose intensity of adriamycin is not as important as it is in young patients. However, in elderly patients, infections are particularly dangerous, especially in patients with low albumin levels.
Abstract
Background/Aims: Among diffuse large B cell lymphoma (DLBCL) patients, determining the appropriate dose and chemotherapy schedule to balance toxicity and efficacy is harder in elderly than in younger patients. Moreover, there are no currently available clinical factors that consistently identify patients who are unfit to receive chemotherapy. Therefore, the clinical characteristics and outcomes of elderly patients with DLBCL and the causes of treatment-related death were investigated in this study. Methods: The clinical characteristics and outcomes of 44 elderly (≥ 70 years of age) patients diagnosed with DLBCL between January 2005 and June 2013 were evaluated. Variable clinical data along with the response rate, overall survival (OS), and causes of treatment-related death or treatment interruption were investigated. Results: The median OS was 18.6 months, and 19 patients completed curative treatment. The mean average relative dose intensity of adriamycin in patients who completed chemotherapy was 0.617, and of these patients, 16 achieved complete remission. Chemotherapy incompletion, infectious complications, extranodal involvement, high lactate dehydrogenase, poor performance status, and low albumin level at diagnosis were related to a shorter OS. However, multivariate analysis revealed that only infections and chemotherapy incompletion were significantly related to poor prognosis. The most common cause of treatment-related death was infection, and patients who had experienced infectious complications tended to have lower albumin levels than those of patients without such complications. Conclusions: In the treatment of elderly lymphoma patients, the dose intensity of adriamycin is not as important as it is in young patients. However, in elderly patients, infections are particularly dangerous, especially in patients with low albumin levels.
참고문헌 (28)
- The Non-Hodgkin’s Lymphoma Classification Project, "Effect of age on the characteristics and clinical behavior of non-Hodgkin’s lymphoma patients", Ann Oncol, 8, pp.973~978 (1997)
- Epelbaum R, "Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma", Isr J Med Sci, 24, pp.533~538 (1988)
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)
- Bairey O, "Non-Hodgkin’s lymphoma in patients 80 years of age or older", Ann Oncol, 17, pp.928~934 (2006)
- Thieblemont C, "Non-Hodgkin’s lymphoma in very elderly patients over 80 years: a descriptive analysis of clinical presentation and outcome", Ann Oncol, 19, pp.774~779 (2008)
- Bernardi D, "Comprehensive geriatric evaluation in elderly patients with lymphoma: feasibility of a patient-tailored treatment plan", J Clin Oncol, 21, pp.754~ (2003)
- Tucci A, "A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy", Cancer, 115, pp.4547~4553 (2009)
- Winkelmann N, "Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma", J Cancer Res Clin Oncol, 137, pp.733~738 (2011)
- Gomez H, "Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin’s lymphoma: results of a multivariate analysis", J Clin Oncol, 16, pp.2065~2069 (1998)
- Pfreundschuh M., "How I treat elderly patients with diffuse large B-cell lymphoma", Blood, 116, pp.5103~5110 (2010)
- Trebouet A, "Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors: a retrospective analysis of 234 cases from the LYSA", Ann Oncol, 24, pp.2612~2618 (2013)
- Terada Y, "Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma", J Exp Clin Cancer Res, 28, pp.116~ (2009)
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346, pp.235~242 (2002)
- Feugier P, "Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte", J Clin Oncol, 23, pp.4117~4126 (2005)
- Fukushima N, "Clinical presentation and outcome in patients of over 75 years old with malignant lymphoma: clinical presentation and outcome in elderly lymphoma patients", Int J Clin Med, 2, pp.246~253 (2011)
- Armitage JO, "Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age", J Am Geriatr Soc, 32, pp.269~273 (1984)
- Wunderlich A, "Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)", Ann Oncol, 14, pp.881~893 (2003)
- Tirelli U, "Non-Hodgkin’s lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study", J Clin Oncol, 6, pp.1708~1713 (1988)
- Soubeyran P, "Diffuse large B-cell and peripheral T-cell non-Hodgkin’s lymphoma in the frail elderly: a phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment", J Geriatr Oncol, 2, pp.36~44 (2011)
- Meguro A, "Rituximab plus 70%cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older", Leuk Lymphoma, 53, pp.43~49 (2012)
- Peyrade F, "Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma:a multicentre, single-arm, phase 2 trial", Lancet Oncol, 12, pp.460~468 (2011)
- Merli F, "Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit”patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi", Leuk Lymphoma, 53, pp.581~588 (2012)
- Shikama N, "A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients", Jpn J Clin Oncol, 41, pp.764~769 (2011)
- Pfreundschuh M, "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)", Lancet Oncol, 9, pp.105~116 (2008)
- Morrison VA., "Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma", Expert Rev Anticancer Ther, 8, pp.1651~1658 (2008)
- Trebouet A, "Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors: a retrospective analysis of 234 cases from the LYSA", Ann Oncol, 24, pp.2612~2618 (2013)
- Monfardini S, "Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin’s lymphomas", Ann Oncol, 16, pp.1352~1358 (2005)
- Weidmann E, "Phase II study of bendamustine in combination with rituximab as firstline treatment in patients 80 years or older with aggressive B-cell lymphomas", Ann Oncol, 22, pp.1839~1844 (2011)